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study by Perier-Muzet et al. highlights
the need for careful sequential skin
examinations, including dermoscopy
and digital monitoring of these patients.
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Indomethacin to the Rescue of
TRAIL-Resistant Melanomas
Rajasekharan Somasundaram1 and Meenhard Herlyn1
Patients with melanomas develop resistance to both conventional- and targeted-
therapy drugs. Promising clinical responses with immune checkpoint reagents
have resulted in renewed interest in the use of biological therapies, although only
subsets of individuals are known to respond to these reagents. Tse et al. now
report on the use of indomethacin, an anti-inflammatory drug, to sensitize
therapy-resistant melanoma cells.
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Melanoma is an aggressive form of skin
cancer with few treatment options. Mel-
anomas are comprised of heterogeneous
subtypes having distinct molecular sig-
natures (Finn et al., 2012). Due to this
complexity, single-agent therapies for
melanomas remain largely unsuccess-
ful. This is because most patients with
metastatic melanoma quickly develop
resistance to both conventional (dacar-
bazine and temozolomide) and targeted
therapies (vemurafenib, dabrafenib
(BRAF inhibitors) and trametinib (MEK
inhibitor)). Even though targeted-therapy
drugs have shown dramatic reductions
in tumor burden when compared with
conventional chemotherapeutic agents,
clinical responses are often relatively
short-lived (Flaherty et al., 2013). In
contrast to targeted-therapy drugs,
clinical responses to immune check-
point reagents (anti-CTLA4 and anti-
PD1) are more durable and long
lasting (Pennock et al., 2011; Hamid
et al., 2013). However, therapy respon-
ses in patients with good clinical
outcome depend on the existence of
sufficient numbers of pre-sensitized anti-
melanoma T cells in the circulation or in
tumor infiltrates. Thus, only subsets of
patients respond to anti-CTLA4 or anti-
PD1 (McDermott and Atkins, 2013). The
targeted-therapy drug, vemurafenib, is
known paradoxically to activate T cells,
increase infiltration of these cells and
upregulate melanoma-associated anti-
gens on tumor cells, resulting in impro-
ved effectiveness by melanoma-reactive
T cells (Cooper et al., 2013). This has
led to combination-therapy trials com-
prising vemurafenib and anti-CTLA4.
Early observations suggest that the
combination-therapy trials are accom-
panied by serious side effects of skin and
liver toxicities (Ribas et al., 2013). The
reasons for these toxicities are poorly
understood; however, T cells reacting to
normal tissue antigens could be one of
the major issues in such trials. Thus,
there is a need to find additional rea-
gents that target tumor survival directly.
Many tumor types, including melanomas,
evade therapies due to a defective ability
of cancer cells to undergo apoptosis.
Thus, targeting apoptotic pathways may
improve drug sensitivities and minimize
toxicities that are frequently associated
with the other therapies.
Apoptosis is a normal physiological
process by which cells undergo pro-
grammed cell death in response to
intrinsic (mitochondrial-mediated) or
extrinsic (tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL)-
mediated) signals (Hersey and Zhang,
2001). Auto-reactive immune cells,
virus-infected cells and DNA-defective
or dysfunctional cells are eliminated by
apoptotic phenomena to maintain tissue
integrity. Apoptosis is generally
accompanied by three main events: (a)
activation of caspase, a primary driver of
apoptosis; (b) DNA and protein degra-
dation; and (c) changes in membrane
morphology leading to phagocytic
elimination by scavenger cells.
Activation of caspase is dependent on
intrinsic mitochondrial–mediated or
classical extrinsic TRAIL– or death
receptor (DR)–mediated signaling
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events. Intrinsic signaling is due to
changes in genetic integrity of the cells,
oxidative stress, low O2 environment
and high cytoplasmic Caþ þ concentra-
tions. It is closely regulated by anti-
apoptotic proteins in the Bcl-2 and
inhibitor of apoptosis (IAP) families.
Bcl-2 and survivin are some of the
anti-apoptotic proteins regulating tumor
TRAIL-mediated apoptosis. The extrinsic
death-receptor pathway is initiated by
binding of TRAIL to its receptors, DR 4
(also known as TRAIL-R1) or DR 5
(TRAIL-R2). Many chemotherapeutic
agents including dacarbazine and temo-
zolomide depend on apoptosis-induced
DNA damage for efficient programmed
tumor cell death. For this, the presence
of TRAIL receptors on tumor cells is one
of the pre-requisites for binding of TRAIL
and activation of extrinsic TRAIL-
mediated signaling of caspase-induced
programmed cell death. However, mel-
anomas are poor responders to TRAIL as
there is frequent down-modulation of
TRAIL receptors and upregulation of
survivin (a negative regulator of cas-
pase-induced apoptosis) resulting in
therapy-related resistance to apoptosis
(Jazirehi and Arle, 2013). Upregulation
of TRAIL receptors and down-
modulation of survivin in melano-
mas will be beneficial in restoring
tumor cell sensitivity to therapeutic
drugs.
In the current issue of Journal of
Investigative Dermatology, Tse et al
(2014) have used a number of in vitro
experiments to demonstrate convin-
cingly the ability of indomethacin, a
non-steroidal anti-inflammatory drug,
to make tumor cells responsive to
TRAIL by enhancing TRAIL-mediated
apoptosis through upregulation of TRAIL
receptor (DR 5) and down-modulation of
survivin. Indomethacin is known to
promote mitochondrial oxidative stress
and the generation of reactive oxygen
species (ROS), which are known to
modulate intrinsic mitochondrial–
mediated signaling (Maity et al., 2009).
The authors demonstrate that ROS-
mediated activation of a transcription
factor, C/enhancer-binding homologous
protein results in upregulation of DR 5
on tumor cells. In addition, indometha-
cin-induced ROS activation results
in inhibition of NF-kB transcription
and subsequent down-modulation of
survivin. NF-kB is a known regulator
of survivin, which is upregulated in
many cancers including melanomas
(Hersey and Zhang, 2001). The authors
have used a number of melanoma cell
lines to confirm these results and have
extended their in vitro studies to other
tumor cell types, including colorectal
and hepato-cellular cancer, and
epithelial carcinoma.
The work by Tse et al., although
conducted in an in vitro setting, is quite
interesting and thought provoking. In the
past, several strategies have been fol-
lowed to modulate TRAIL-mediated
apoptosis with limited success. Such
studies include specific targeting of
anti-apoptotic or IAP protein families
such as Bcl-2, Bcl-x, Mcl-1 and survivin.
Also, studies involving cisplatin or dox-
orubicin and cytokines such as tumor
necrosis factor (TNF)-a to upregulate
TRAIL receptors and inhibition of NF-
kB did not fare too well in pre-clinical
experiments (Jazirehi and Arle, 2013).
Some of the failures could also be attri-
buted to the delivery of small molecule
inhibitors or anti-sense oligonucleotides
targeting Bcl family proteins to the tumor
site. In contrast, indomethacin has been
used in the clinics as an anti-inflam-
matory agent and also in the treatment
of pre-cancerous adenomatous polyps
(Barker and Clevers 2007). However,
the efficacy of indomethacin, either
alone or in combination with other
therapeutic drugs as reported by Tse
et al., must now be extended to pre-
clinical animal models. Results from
such studies may have major implica-
tions on the treatment of all cancers,
including melanoma.
CONFLICT OF INTEREST
The authors state no conflict of interest.
REFERENCES
Barker N, Clevers H (2007) Mining the Wnt path-
way for cancer therapeutics. Nat Rev Drug
Discov 5:997–1015
Cooper ZA, Frederick DT, Ahmed Z et al. (2013)
Combining checkpoint inhibitors and BRAF-
targeted agents against metastatic melanoma.
Oncoimmunology 2:e24320
Finn L, Markovic SN, Joseph RW (2012) Therapy
for metastatic melanoma: the past, present,
and future. BMC Med 10:23
Flaherty KT, Robert C, Hersey P et al. (2013)
Improved survival with MEK inhibition in
BRAF-mutated melanoma. N Engl J Med
367:107–14
Hamid O, Robert C, Daud A et al. (2013) Safety
and tumor responses with lambrolizumab
(anti-PD-1) in melanoma. N Engl J Med
369:134–44
Hersey P, Zhang XD (2001) How melanoma cells
evade trail-induced apoptosis. Nat Rev Can-
cer 1:142–50
Jazirehi AR, Arle D (2013) Epigenetic regulation of
the TRAIL/Apo2L apoptotic pathway by histone
deacetylase inhibitors: an attractive approach
to bypass melanoma immunotherapy resis-
tance. Am J Clin Exp Immunol 2:55–74
Maity P, Bindu S, Dey S et al. (2009) Indometha-
cin, a non-steroidal anti-inflammatory drug,
develops gastropathy by inducing reactive
oxygen species-mediated mitochondrial
pathology and associated apoptosis in gastric
mucosa: a novel role of mitochondrial aconi-
tase oxidation. J Biol Chem 284:3058–68
McDermott DF, Atkins MB (2013) PD-1 as a
potential target in cancer therapy. Cancer
Med 2:662–7
Pennock GK, Waterfield W, Wolchok JD (2011)
Patient responses to ipilimumab, a novel immu-
nopotentiator for metastatic melanoma: how
different are these from conventional treatment
responses? Am J Clin Oncol 35:606–11
Ribas A, Hodi FS, Callahan M et al. (2013)
Hepatotoxicity with combination of vemura-
fenib and ipilimumab. N Engl J Med
368:1365–6
Tse AK-W, Cao H-H, Cheng C-Y et al. (2014)
Indomethacin sensitizes TRAIL-resistant mel-
anoma cells to TRAIL-induced apoptosis
through ROS-mediated upregulation of death
receptor 5 and downregulation of survivin.
J Invest Dermatol 134:1397–407
Clinical Implications
 Tumor cells frequently down-modulate TRAIL receptors and upregulate
survivin to escape apoptosis.
 Indomethacin, a non-steroidal anti-inflammatory drug, makes tumor cells
sensitive to TRAIL-mediated apoptosis signaling by upregulating TRAIL
receptor (DR 5) and down-modulating survivin.
 Therapy-resistant tumor cells are now reported to be responsive to drugs
in the presence of indomethacin.
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